


wherein X is CR<sup>1A</sup>, CHR<sup>1A</sup>, N, NR<sup>1B</sup>, O, or S, where R<sup>1A</sup> is as defined for R<sup>3</sup> to R<sup>9</sup> below, and where R<sup>1B</sup> is as defined for R<sup>10</sup> below;

U is C, CH, or N; and

the dotted lines indicate optional bonds; or

A is a group having the formula



wherein U is C, CH, or N;

Y is CR<sup>2A</sup>, CHR<sup>2A</sup>, N, NR<sup>2B</sup>, O, or S, where R<sup>2A</sup> is as defined for R<sup>3</sup> to R<sup>9</sup> below and where R<sup>2B</sup> is as defined for R<sup>10</sup> below; and

the dotted lines indicate optional bonds;

n is 0, 1, 2, 3, 4, or 5, and m is 0, 1, 2, 3, 4, or 5;

Z is CH<sub>2</sub>, O, S, CO, SO, or SO<sub>2</sub>, provided that if n is 0 then Z is CH<sub>2</sub>;

R<sup>3</sup>-R<sup>9</sup> and R<sup>11</sup> to R<sup>12</sup> are independently selected from hydrogen, halogen, cyano, nitro, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, hydroxy, hydroxy-C<sub>1-6</sub>-alkyl, C<sub>1-6</sub> alkoxycarbonyl, C<sub>3-8</sub> cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, C<sub>1-6</sub> alkylcarbonyl, phenylcarbonyl, halogen substituted phenylcarbonyl, trifluoromethyl, trifluoromethylsulfonyloxy, C<sub>1-6</sub> alkylsulfonyl, aryl and heteroaryl, or two adjacent groups taken from R<sup>3</sup> - R<sup>9</sup> may together form a methylenedioxy group, or two adjacent groups R<sup>7</sup> - R<sup>9</sup> may together form a cyclopentyl or cyclohexyl ring which may be substituted with one or more methyl groups, or one of R<sup>3</sup>-R<sup>9</sup> may alternatively be a group -NR<sup>13</sup>R<sup>14</sup> wherein R<sup>13</sup> is as defined for R<sup>10</sup> below and R<sup>14</sup> is hydrogen, C<sub>1-6</sub> alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub> alk(en/yn)yl, aryl, heteroaryl, aryl-C<sub>1-6</sub> alkyl, or heteroaryl-C<sub>1-6</sub>-alkyl;

R<sup>10</sup> is

- hydrogen, C<sub>1-6</sub> alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub> cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, aryl, heteroaryl, aryl-C<sub>1-6</sub> alkyl, heteroaryl-C<sub>1-6</sub>-alkyl, acyl, thioacyl, C<sub>1-6</sub>-alkylsulfonyl, trifluoromethylsulfonyl; arylsulfonyl, or heteroarylsulfonyl;
- R<sup>15</sup>VCO- wherein V is O or S and R<sup>15</sup> is C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub> cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, aryl, or heteroaryl; or
- a group R<sup>16</sup>R<sup>17</sup>NCO- or R<sup>16</sup>R<sup>17</sup>NCS- wherein R<sup>16</sup> and R<sup>17</sup> are independently selected from hydrogen, C<sub>1-6</sub> alk(en/yn)yl, C<sub>3-8</sub> cycloalk(en)yl, C<sub>3-8</sub> cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, heteroaryl, or aryl, or R<sup>16</sup> and R<sup>17</sup> together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, morpholinyl, or perhydroazepin group;

or an acid addition salt thereof.

6. (Amended) A compound according to claim 1 wherein Z is CH<sub>2</sub> and n + m is 0, 1, 2, 3, 4, 5, or 6.

11. (Amended) A compound of claim 1 wherein Z is CH<sub>2</sub> and n + m is 0, 1, 2, 3, 4, 5, or 6 and R<sup>3</sup>-R<sup>9</sup> and R<sup>11</sup>-R<sup>12</sup> is hydrogen, halogen, cyano, nitro, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy, hydroxy, hydroxy-C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxycarbonyl and trifluoromethyl; and R<sup>10</sup> is hydrogen.

13. (Amended) A compound according to claim 1 which is

1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)-1,2,3,6-

tetrahydropyridine,

1-(2-(5-Fluoro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)-1,2,3,6-

tetrahydropyridine,

1-(3-(5-Fluoro-3-benzofuranyl)-1-propyl)-4-(1H-indol-4-yl)-1,2,3,6-

tetrahydropyridine,

1-(2-(6-Chloro-1H-indol-3-yl)-4-(1H-indol-4-yl)piperidine,

1-(2-(4-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperidine,

4-(1H-Indol-4-yl)-1-(2-(5-methyl-1H-indol-3-yl)ethyl)piperidine,

4-(1H-Indol-4-yl)-1-(2-(1H-indol-3-yl)ethyl)piperidine,

4-(1H-Indol-4-yl)-1-(3-(4-methyl-3-benzofuranyl)-1-propyl)piperidine,

or a pharmaceutically acceptable acid addition salt thereof.

14. (Amended) A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof and at least one pharmaceutically acceptable carrier or diluent.

17. (Amended) A method for the treatment of a disorder or disease of a living animal body, which is responsive to the inhibition of serotonin reuptake and antagonism of 5-HT<sub>1A</sub> receptors comprising administering to such a living animal

body, a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof.

A8

18. (Amended) A method for the treatment of an affective disorder in a living animal body, comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof.

Please add the following new claims.

19. (New) The method of claim 17 wherein said living animal body is a human.

20. (New) The method of claim 18 wherein said living animal body is a human.

21. (New) The method of claim 20 wherein said affective disorder is selected from the group consisting of depression, psychosis and anxiety disorder.

22. (New) The method of claim 20 wherein said affective disorder is an anxiety disorder selected from the group consisting of general anxiety disorder, panic disorder and obsessive compulsive disorder.